Anders Carlsson, PhD, Chief Executive Officer
Dr Carlsson has more than 30 years of industrial experience in the area of pharmaceutical development, specializing within the fields of applied colloid and surface science, liquid and semi-solid pharmaceutical formulations, and drug delivery systems. Previous appointments include Business Development Director at Phares Drug Delivery, and Research Director at Lipocore (formally part of Scotia LipidTeknik), where he was responsible for development of lipid formulations, primarily for pharmaceutical applications, but also for cosmetics and food. Dr Carlsson is a co-inventor on 33 patents. He has a PhD in Physical Chemistry from Lund University, Sweden, and has co-authored some 40 scientific articles and publications.
Bengt Herslöf, PhD, Prof, Senior Scientist
Dr Herslöf has over 40 years of experience working with lipid sciences in the areas of pharmaceuticals and food, including positions at Karlshamns AB and KabiVitrum AB. In 1986 he co-founded and was the CEO of LipidTeknik AB, which became LTP Lipid Technologies Provider AB in 2001, and was acquired by DSM in 2006. Between 1997 and 2001 he was an Executive Board Director of Scotia Holdings plc, listed on the London Stock Exchange, LipidTeknik´s former parent company. Dr Herslöf received his PhD in Organic Chemistry at the University of Lund, Sweden, and is a professor in Analytical Chemistry at Stockholm University. He has also been a visiting professor at Rutgers University, NJ, USA. He is author and co-author of some 50 scientific publications and 25 patents.
Jan Holmbäck, PhD, Chief Scientific Officer
Dr Holmbäck has more than 30 years of experience from the pharmaceutical industry in the fields of analytical and organic chemistry. He is specialized in the characterization of lipid materials, particularly by spectroscopic and chromatographic methods, and the use of lipids in drug delivery systems. Previous appointments include positions at Kabi, Pharmacia, and as Senior Scientist at LipoCore. Dr Holmbäck holds a PhD in Organic Chemistry from the Royal Institute of Technology, Stockholm.
Olle Holmertz, MBA, Chief Financial Officer
Mr Holmertz has 15 years of experience from positions as CFO, Investment manager and Board member in technology companies (medical and other) and venture capital firms. Previous appointments include CFO of LTP Lipid Technologies Provider AB, and CIMON Medical AB. Mr Holmertz has an MSc in Business Administration from Lund University, Sweden.
Board of directors
Ola Flink, Pharmacist, (Chairman)
Brings experience from more than 30 years in the pharmaceutical drug development industry, including positions with Karolinska Development, AstraZeneca, Apoteksbolaget, ACO Läkemedel and Kabi Invent. Board member in several biotech companies.
Dr Haering is CEO of Cerbios-Pharma SA (Switzerland), a company which specializes in the development and manufacturing of chemical and biological APIs. Dr Haering has since 2009 been responsible for renewing the company image with international branding activities and implementation of a new strategy promoting innovation in technologies, products and services for both the Chemical and Biological Division. Prior to this Dr Haering held different positions at the Helsinn group. Dr Haering holds a Ph.D. in Natural Sciences from the Swiss Federal Institute of Technology in Zürich (ETHZ).
Mr Hedman is Chairman of the Board and Business Development Director of Aurena Laboratories AB, and has been involved in the medical device and pharma industry for over 20 years. Mr Hedman co-founded Aurena Laboratories in the year 2000, a company which has developed a range of successful sprayable OTC- and wound and skincare products for the international pharmaceutical markets. Mr Hedman was International Sales & Marketing Manager and Product Developer for the Swedish respiratory care company Aiolos Medical during the years 1990 to 2000.
Bengt Herslöf, PhD, Prof.
Olle Holmertz, MBA
Mona Ståhle, Professor and Dermatologist
Dermatology and Venereology Unit, Karolinska Universitetssjukhuset, 171 76 Stockholm, Sweden
Advises Lipidor within the field of dermatology.
Conny Bogentoft, PhD, Assoc Prof, Senior Advisor
Dr Bogentoft has more than 30 years of experience in the pharmaceutical industry gained at senior research and development management positions and as a member of the board of directors for a number of companies. Previous appointments include CEO of Karolinska Development, Vice President of Astra Arcus, President of Kabi Invent, Research Director at ACO Läkemedel, and Chairman of the Swedish Academy of Pharmaceutical Sciences. Dr Bogentoft is an Associate Professor in Pharmaceutical Chemistry and holds a PhD in Medicinal Chemistry.